Detalhe da pesquisa
1.
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Blood
; 141(2): 156-167, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714312
2.
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN.
Haematologica
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695123
3.
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Br J Haematol
; 202(5): 942-952, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246588
4.
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Blood
; 137(5): 637-645, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32870269
5.
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Lancet Oncol
; 22(11): 1597-1608, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34672961
6.
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
Lancet Haematol
; 10(7): e510-e520, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407142
7.
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.
Leukemia
; 34(8): 2064-2073, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32265500
8.
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
Leuk Lymphoma
; 61(3): 650-659, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31647335
9.
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.
Leuk Lymphoma
; 62(8): 2040-2043, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653205